Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Playing It Safe? Hahn's Biosimilar View

Nov 24 2019

• By Derrick Gingery

Stephen Hahn, President Trump’s nominee for commissioner of the FDA, at his Senate confirmation hearing today — US FDA Commissioner nominee Stephen Hahn awaits the start of his Senate confirmation hearing on 20 November, where he responded to questions about biosimilars, vaping and other issues. • Source: Derrick Gingery

Related Content

US FDA Nominee Makes A Good First Impression, But This Is Still An Odd Transition

Nov 22 2019

Biosimilar User Fee Collections Drop Well Below Estimates, But US FDA Not Worried

Jun 10 2019

After Biosimilar Fee Collections Fall Short, US FDA Modifies Carryover Spend-Down Plan

Oct 09 2019

AbbVie's 'Unjustified' Humira Settlements Divide Market, Class Action Claims

Mar 20 2019

Drug Development Questions Dominate Hahn's Confirmation, Despite Talk About E-Cigs

Nov 20 2019

Make The ‘Purple Book’ More Orange, US FDA Told At Biosimilars Hearing

Sep 05 2018

Related Companies

Teva Pharmaceutical Industries Ltd.

Additional Topics

United States Biosimilars Leadership Regulation FDA BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window